| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | selumetinib:tretinoin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | 0.0024 | 1 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.0027 | 1 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | -0.0027 | 1 |